Sandu Pharmaceuticals opened higher at ₹37.88, compared with its previous close of ₹37.68. In the last trading session on 12 Nov 2026, the stock traded between ₹36.22 and ₹39.14, with an average traded price of ₹38.34. It showed a sideways intraday trend.
An investment of ₹10,000 made 5 years ago in Sandu Pharmaceuticals is now worth
₹ 7,751.00
Resulting in a loss of
₹ 2,249.00 (22.49%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+0.22 (+0.58%)
Day High
₹39.14
Day Low
₹36.22
Day Open
₹37.88
Prev Close
₹37.68
Volume
4,228
Value Traded
₹0.02 Cr
1W Return
7.58%
1M Return
3.95%
3M Return
-3.95%
6M Return
-2.87%
1Y Return
-12.15%
Market Cap (₹ Cr.)
37
PE Ratio
20.60
PB Ratio
1.03
Dividend Yield
2.65%
ROE
3.69%
ROCE
5.18%
Book Value (₹)
36.48
Face Value (₹)
10.00
EPS (TTM)
0.34
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
7.58%
6 Weeks
-
1 Month
3.95%
3 Months
-3.95%
9 Months
8.13%
Sandu Pharmaceuticals director Dr Neeti Gupta changes name post marriage
Sandu Pharmaceuticals notified BSE of director name change. Dr Neeti Madan Kapre changed name to Dr Neeti Gupta. Change occurred due to marriage. DIN and designation remain unchanged.
1mo agoSandu Pharma appoints Balram Viswanathan as CMD, Neeti Kapre as independent director
All eight resolutions at Sandu Pharma's 41st AGM passed with 99.99% shareholder approval. Balram Viswanathan redesignated as CMD for three years effective July 11, 2026. Dr Neeti Madan Kapre appointed as Non-Executive Independent Director for five years. Voting participation stood at 44.49% of eligible shares among 10,523 shareholders.
2mo agoSandu Pharmaceuticals appoints Dave & Dave as statutory auditors for five years
Sandu Pharmaceuticals appointed M/s Dave & Dave as statutory auditors for FY27 to FY31. Outgoing auditors M/s Dileep and Prithvi completed two five-year terms. Shareholders approved the move at the AGM held on September 11, 2026. New firm holds valid peer review certificate until March 31, 2028.
2mo agoSandu Pharmaceuticals schedules 41st AGM for September 11, 2026
Sandu Pharmaceuticals Limited will hold its 41st AGM on September 11, 2026, via video conference. Remote e-voting opens on September 8 and closes on September 10. The record date for dividend eligibility is September 4, 2026.
2mo agoSandu Pharmaceuticals FY26 net profit rises 23.2% to ₹176.62 lakh
Sandu Pharmaceuticals reported a 23.2% increase in FY26 net profit to ₹176.62 lakh, supported by a 4.1% rise in revenue to ₹6,993.45 lakh. The board recommended a final dividend of ₹1 per share and appointed M/s. Dave & Dave as statutory auditors.
2mo agoSandu Pharmaceuticals appoints Viswanathan as Chairman and MD
Sandu Pharmaceuticals Limited has redesignated Shri Balram Viswanathan as Chairman and Managing Director for a term of three years effective July 11, 2026. The board also appointed Dr. Neeti Madan Kapre as an Additional Non-Executive Independent Director for a five-year term. These decisions follow the demise of former Managing Director Shri Umesh B. Sandu on June 19, 2026.
4mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,898.30 | +0.71% | ₹4,55,465.76 | 41.20 | +9.60% | |
| ₹11,502.50 | +0.15% | ₹3,05,355.23 | 90.40 | +76.42% | |
| ₹4,689.50 | -0.80% | ₹1,78,373.51 | 85.50 | +22.61% | |
| ₹2,434.80 | +1.45% | ₹1,31,555.22 | 97.10 | +146.13% | |
| ₹1,204.60 | -0.12% | ₹1,20,159.31 | 28.00 | +26.61% | |
| ₹1,388.90 | +0.17% | ₹1,15,928.74 | 42.00 | +12.96% | |
| ₹1,409.30 | +0.07% | ₹1,13,851.49 | 39.90 | -7.24% | |
| ₹2,666.00 | +1.04% | ₹1,10,117.82 | 48.10 | +17.44% | |
| ₹1,816.20 | +0.50% | ₹1,04,500.13 | 26.00 | +53.45% | |
| ₹2,020.80 | +0.29% | ₹92,409.16 | 17.60 | -0.64% | |
| ₹2,641.50 | -0.69% | ₹74,549.65 | 51.60 | +42.95% | |
| ₹5,187.50 | -2.16% | ₹62,024.34 | 30.50 | -10.06% |
An investment of ₹10,000 made 5 years ago in Sandu Pharmaceuticals is now worth
₹ 7,751.00
Resulting in a loss of
₹ 2,249.00 (22.49%)
Note: Past profits do not guarantee future returns.
